Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
US10927184B2 · kind B2 · utility
5Cited by
56References
26Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Nov 15, 2018 |
| Grant date | Feb 23, 2021 |
| Priority date | — |
| Expiry date | Nov 15, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides compositions and methods for treating diseases associated with expression of CD19. The invention also relates to chimeric antigen receptor (CAR) specific to CD19, vectors encoding the same, and recombinant T cells comprising the CD19 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD19 binding domain.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.